AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
By Colin Kellaher
AbbVie has filed for accelerated Food and Drug Administration approval of its proposed antibody-drug conjugate for patients with a form of lung cancer.
AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with c-Met protein overexpression.
The North Chicago, Ill., biopharmaceutical company said there are currently no approved anti-cancer therapies specifically for c-Met overexpressing non-small cell lung cancer, which is associated with a poor prognosis.
Antibody-drug conjugates, known as ADCs, work like guided missiles by pairing antibodies with toxic agents to fight cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2024 12:48 ET (16:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now